What is Alvotech?
Alvotech is a global biopharmaceutical company dedicated to the development and manufacturing of biosimilar medicines. Through its subsidiaries, Alvotech focuses on creating high-quality, cost-effective alternatives to existing biologic therapies across critical therapeutic areas such as autoimmune disorders, ophthalmology, and oncology. The company's pipeline includes promising candidates like AVT02, a biosimilar to Humira, and AVT04, a biosimilar to Stelara, aimed at treating a wide range of inflammatory conditions. With a commitment to patient access and innovation, Alvotech is strategically positioned to address unmet medical needs worldwide.
How much funding has Alvotech raised?
Alvotech has raised a total of $688.2M across 7 funding rounds:
Other Financing Round
$300M
Share Placement
$35M
Multiple Rounds
$136M
Debt
$100M
Debt
$117.2M
Other Financing Round (2019): $300M with participation from Fuji Pharma
Share Placement (2021): $35M led by Baxter Healthcare, ATHOS, and Shinhan Financial Group
Debt (2022): $70M supported by Sculptor Capital, Farallon Capital Management, Morgan Stanley, and Oaktree Capital Management
Debt (2022): $16M featuring Landsbankinn HF
Debt (2022): $50M backed by Alvogen
Debt (2023): $100M with participation from At&p Holding
Debt (2026): $117.2M led by GoldenTree Asset Management
Key Investors in Alvotech
Fuji Pharma
Fuji Pharma is a pharmaceutical company with a focus on new drug development, generics, and biosimilars, particularly active in women's healthcare and acute medical care, including oncology. Their involvement suggests a strategic partnership in manufacturing or market access.
GoldenTree Asset Management
GoldenTree Asset Management is a global asset management firm specializing in credit investments across various sectors, including private credit and distressed debt. Their participation indicates a financial backing strategy focused on debt instruments.
Sculptor Capital
Sculptor Capital Management is an alternative asset management firm with diverse investment strategies including multi-strategy and credit. Their investment points to a sophisticated financial backing approach.
What's next for Alvotech?
The recent major strategic investment in Alvotech signals a strong confidence from its backers in the company's future prospects and its role in expanding access to biosimilar treatments. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and support global commercialization efforts. Alvotech's continued focus on a diverse portfolio of biosimilars, including those targeting major blockbuster drugs, positions it for significant expansion and market penetration in the coming years. The company's strategic financing activities indicate a phase of aggressive scaling and market consolidation.
See full Alvotech company page
